Sign In
Buy CELU
$1.02
-0.0400 (-3.77%)
At Close: Jun 03, 2026
Celularity Releases CEO Letter to Shareholders
04:15pm, Wednesday, 03'rd Jun 2026
FLORHAM PARK, N.J., June 03, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) ("Celularity" or the "Company"), a longevity-focused regenerative and cellular medicine company pioneering placenta
Celularity Appoints Rick Gonzalez as Chief Commercial Officer
08:00am, Wednesday, 03'rd Jun 2026
FLORHAM PARK, N.J., June 03, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a longevity-focused regenerative and cellular medicine company pioneering
Celularity Receives Nasdaq Notice Regarding Form 10-Q
05:15pm, Friday, 29'th May 2026
FLORHAM PARK, N.J., May 29, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”), a longevity-focused regenerative and cellular medicine company, today announced that it receive
Celularity Announces Filing of Form 10-K, Regains Nasdaq Compliance and Highlights Continued Strategic Transformation
04:30pm, Friday, 01'st May 2026
Company advances focused strategy, strengthens balance sheet and positions business for long-term growth Company advances focused strategy, strengthens balance sheet and positions business for long-te
NEXGEL Appoints Ian Blackman as Chief Financial Officer
09:00am, Monday, 27'th Apr 2026
Veteran Financial and M&A Leader Appointed to Integrate Acquisition of Celularity, Scale the Business and Accelerate Growth LANGHORNE, Pa., April 27, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL�
Transaction expected to approximately triple NEXGEL's annual revenue to approximately $35 million and is expected to be immediately accretive to profitability Licensing and acquiring a diversified sui
Celularity Announces Closing of Transaction with NexGel
08:30am, Tuesday, 21'st Apr 2026
FLORHAM PARK, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellular medicine company, today announced the closing of
Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing
04:35pm, Friday, 17'th Apr 2026
FLORHAM PARK, N.J., April 17, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”), a longevity-focused regenerative and cellular medicine company, today announced that on April
KALA BIO (NASDAQ:KALA) vs. Celularity (NASDAQ:CELU) Financial Survey
02:02am, Monday, 06'th Apr 2026
Celularity (NASDAQ: CELU - Get Free Report) and KALA BIO (NASDAQ: KALA - Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses ba
FLORHAM PARK, N.J., March 12, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company focused on longevity science
EXCLUSIVE: NexGel To Acquire Regenerative Biomaterial Portfolio From Celularity, Expects To Triple Revenue
08:30am, Tuesday, 10'th Mar 2026
The transaction represents the most significant milestone in the company's history.
Celularity Secures $35 Million Strategic License Deal, Strengthens Capital Position to Advance Longevity-Focused Strategy
08:30am, Tuesday, 10'th Mar 2026
FLORHAM PARK, N.J., March 10, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company focused on longevity science
Celularity Receives $12.2 Million from Sale of New Jersey Net Operating Losses
08:30am, Tuesday, 10'th Feb 2026
FLORHAM PARK, N.J., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellular medicine company, today announced receipt of $12.
Celularity CEO Comments on Centers for Medicare & Medicaid Services' Withdrawal of Skin Substitute Local Coverage Determinations
08:30am, Friday, 26'th Dec 2025
While Celularity's Biovance® and Biovance 3L products remained eligible for Medicare coverage under the now-withdrawn LCDs, Celularity CEO Dr. Robert J. Hariri welcomed the recent action taken under
Celularity Announces Closing of Financing Transactions
04:01pm, Monday, 22'nd Dec 2025
FLORHAM PARK, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases,
